Shares of Enhabit, Inc. (NYSE:EHAB – Get Rating) have been given an average recommendation of “Hold” by the eight ratings firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $16.71.
Several analysts have recently weighed in on EHAB shares. Citigroup raised their target price on Enhabit from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Friday, February 17th. UBS Group initiated coverage on Enhabit in a report on Thursday, December 8th. They set a “sell” rating and a $12.00 price objective on the stock. Credit Suisse Group reiterated a “neutral” rating and set a $15.00 target price on shares of Enhabit in a research note on Thursday, February 16th. CJS Securities assumed coverage on shares of Enhabit in a research note on Tuesday, December 13th. They issued a “market perform” rating and a $18.00 price target for the company. Finally, Stifel Nicolaus upped their price target on shares of Enhabit from $17.00 to $18.00 in a report on Wednesday, February 15th.
Institutional Trading of Enhabit
A number of hedge funds have recently bought and sold shares of EHAB. IFP Advisors Inc acquired a new position in shares of Enhabit in the 3rd quarter valued at about $39,000. CI Investments Inc. acquired a new position in shares of Enhabit in the 2nd quarter valued at about $27,000. Bessemer Group Inc. acquired a new position in shares of Enhabit in the 3rd quarter valued at about $26,000. Lazard Asset Management LLC acquired a new position in Enhabit in the third quarter worth approximately $34,000. Finally, South Dakota Investment Council acquired a new position in Enhabit in the third quarter worth approximately $45,000. 95.55% of the stock is owned by hedge funds and other institutional investors.
Enhabit Stock Performance
Enhabit Company Profile
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
See Also
- Get a free copy of the StockNews.com research report on Enhabit (EHAB)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts DefendĀ
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.